.avif)
Lantheus Email Format
Pharmaceutical Manufacturing
・
501-1,000 employees
・
Bedford, MA, USA
Lantheus is a radiopharmaceutical-focused company delivering diagnostic and therapeutic solutions across oncology, neurology, and cardiology to clinicians worldwide.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
first.last@lantheus.com
Company Overview
Industry
Pharmaceutical Manufacturing
Founded
1956
Headquarters
Bedford, MA, USA
Revenue
$1B-$2.5B
FUNDING Stage
Public
Website
Key Executives
Mary Anne Heino (Executive Chairperson and Interim CEO), Robert J. Marshall, Jr. (Chief Financial Officer and Treasurer), Lee Anne Howe (Chief Information Officer)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Lantheus?
Lantheus uses the first.last format on lantheus.com, so Jane Smith would be jane.smith@lantheus.com.
What key products does Lantheus sell for oncology imaging?
Lantheus markets PYLARIFY, a PSMA-targeted PET imaging agent for prostate cancer, alongside PYLARIFY AI, an AI platform for standardized PSMA quantification. The company also has late-stage radiotherapeutic candidates PNT2002 and PNT2003 in its oncology pipeline.
Where is Lantheus headquartered and what therapeutic areas does it focus on?
Lantheus is headquartered in Bedford, MA and focuses on radiopharmaceuticals across oncology, neurology, and cardiology, developing both radiodiagnostics and radiotherapeutics designed to help clinicians find, fight, and follow disease.
How can I find and verify a Lantheus contact's email address for outreach?
Since Lantheus follows the first.last@lantheus.com format, you can build an address directly from a contact's name. A tool like Clay can help you verify those addresses at scale and enrich your prospect list with accurate Lantheus contacts.
Does Lantheus have a cardiology diagnostic product in its portfolio?
Yes, Lantheus received FDA approval for Flyrcado (flurpiridaz F 18) injection in 2024, a cardiac PET imaging agent, and also markets the long-established DEFINITY ultrasound contrast agent and Cardiolite for cardiac imaging.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating